Navigation Links
Orchid Cellmark Appoints William J. Thomas Vice President and General Counsel
Date:11/20/2007

PRINCETON, N.J., Nov. 20 /PRNewswire-FirstCall/ -- Orchid Cellmark Inc. (Nasdaq: ORCH), a leading worldwide provider of identity DNA testing services, today announced the appointment of William J. Thomas, Esq. as Vice President and General Counsel.

Mr. Thomas was formerly Senior Vice President and General Counsel for Cytogen Corporation responsible for all legal matters including the management of outside general and intellectual property counsel. Prior to joining Cytogen, Mr. Thomas was a senior partner with the law firm of Wilmer Cutler Pickering Hale and Dorr LLP. Previously, he was a partner at the law firm Buchanan Ingersoll P.C. Mr. Thomas has more than 20 years of experience in the areas of general corporate issues, mergers and acquisitions, securities law compliance and managing intellectual property. Mr. Thomas received a J.D. degree from Fordham University School of Law and a B.A. degree in Political Science from Rutgers University.

Thomas A. Bologna, President and Chief Executive Officer of Orchid said, "I am pleased that Bill is joining Orchid's management team. He is a proactive and business oriented General Counsel with the legal experience and skill set that we believe will complement our management team well."

About Orchid Cellmark

Orchid Cellmark Inc. is a leading international provider of DNA testing services for human identity testing and agricultural applications. In the human identity area, Orchid Cellmark provides DNA testing services for forensic investigation, paternity testing and family relationship analysis and security applications. In the agriculture field, Orchid Cellmark provides DNA testing services for selective trait breeding. Orchid Cellmark's strong market positions in these segments reflect the company's accredited laboratories in the U.S. and U.K., its innovative genetic analysis technologies and expertise and the world-renowned Cellmark brand that has been associated with exceptional quality, reliability and customer service for nearly two decades. More information on Orchid Cellmark can be found at http://www.orchid.com.

All statements in this press release that are not historical are forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995., including but not limited to Orchid Cellmark's belief that Mr. Thomas has the legal experience and skill set that will complement its management team well. Such statements are subject to the risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, Orchid Cellmark's ability to timely and successfully integrate ReliaGene's business, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of Orchid Cellmark's products and services, dependence on government funding and collaborations, regulatory approvals, competition, intellectual property of others, patent protection, litigation, the timing of release of federal funds, the timing and amount of contracts put up for bid, Orchid Cellmark's ability to timely and successfully initiate operational efficiencies, lower overhead and other remedial measures and Orchid Cellmark's continued relationship with DEFRA. These risks and other additional factors affecting these statements and Orchid Cellmark's business are discussed under the headings "Risks Related to Our Business" and "Risks Associated with Our Common Stock" in Orchid Cellmark's Annual Report on Form 10-K for the year ended December 31, 2006, as filed with the Securities and Exchange Commission, and in other filings made by Orchid Cellmark with the Securities and Exchange Commission from time to time. Orchid Cellmark expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Orchid Cellmark's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based, except as may be required by law.

Contacts

Investors: Media:

Mary Bashore Barbara Lindheim

Orchid Cellmark Inc. GendeLLindheim BioCom Partners

(609) 750-2324 (212) 918-4650


'/>"/>
SOURCE Orchid Cellmark Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Orchid Cellmark Reports Third Quarter 2007 Financial Results
2. WorldHeart Appoints David Pellone Chief Financial Officer
3. Novo Nordisk Appoints New Leader of North American Business
4. The American Liver Foundation Appoints Rick Smith, a Twenty-Year Veteran of The MS Society, as Chief Executive Officer
5. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
6. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
7. Resonant Medical Appoints New Vice President of Global Sales
8. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
9. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
10. EPI-Q Opens East Coast Office and Appoints Vice President-Business Development
11. President George W. Bush Appoints Susan G. Komen for the Cure Founder as Chief of Protocol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... , ... January 16, 2017 , ... ... attorney, science teacher, http://www.ageofautism.com/legal , Sharon Kleyne, America’s leading water educator, ... to her nationally syndicated radio program, The Sharon Kleyne Hour Power of Water, ...
(Date:1/16/2017)... PARK CITY, UT (PRWEB) , ... January 16, 2017 , ... ... expensive disease not only to treat, but to test for, as well. The money ... $88.7 billion every year.(1) Doctors in the U.S. screen patients for cancer more than ...
(Date:1/16/2017)... ... January 16, 2017 , ... NexTec Group has been selected as a ... honored for their accomplishments in the field of midmarket financial software. , Members of ... and innovation. Selection is not based on revenue and those firms chosen represent a ...
(Date:1/15/2017)... ... January 15, 2017 , ... Whole Health Supply, LLC is announcing the release of an updated ... avenues for purchase. , The 2017 edition has wide jaws that will accommodate nails ... boomers as well as diabetics. This handle is reinforced for extra strength when pressing down ...
(Date:1/15/2017)... ... January 15, 2017 , ... San ... in eight Bay Area counties for 2017. Almost 1,000 nominations were submitted and ... the award process. Results were announced the magazine’s January 2017 issue . ...
Breaking Medicine News(10 mins):
(Date:1/15/2017)... , January 16, 2017 Le ... innovants à base de collagène pour la régénération de tissus ... au poste de directeur général avec effet immédiat. ... Bill est un ... a occupé plusieurs postes de gestion générale et de direction ...
(Date:1/13/2017)... , Jan. 13, 2017 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: ... VP of Corporate Finance and Investment Banking at Eli Lilly ... effective immediately. Mr. Bott brings over 28 years of senior ... ... Martin Bott has established a significant leadership position in ...
(Date:1/13/2017)... York , January 13, 2017 ... prevalence of AIDS will collectively contribute to the demand for ... to reach a value of US$ 551.0 Mn by 2016 ... will remain the most lucrative markets for western blotting, whereas ... the market globally. ...
Breaking Medicine Technology: